Acute onset of obsessive-compulsive symptoms and/or restrictive eating behavior, accompanied by at least two of the following symptoms: anxiety, sensory hypersensitivity, depressed mood, motor symptoms (e.g., dysgraphia, tics, stereotypic movements), behavioral regression, academic decline (e.g., attention/memory impairments, ADHD-like symptoms), mood swings (e.g., irritability, aggression, oppositional behavior), somatic signs (e.g., sleep disturbances, mydriasis, enuresis, other urinary tract
Conditions
Interventions
Group 1: Patients presenting to pediatric hospitals (particularly to neuropediatric departments) with symptoms suggestive of PANS for the purpose of excluding alternative diagnoses will be enrolled.
Sponsors
Klinik für Neuropädiatrie, Universitätsklinikum Schleswig-Holstein, Campus Kiel
Eligibility
Sex/Gender
All
Age
No minimum to 17 Years
Inclusion criteria
Inclusion criteria: All patients presenting from July 1, 2025 onward to participating pediatric hospitals in Germany for differential diagnostic evaluation to exclude alternative conditions, and who meet the predefined inclusion criteria, will be included. These are defined as abrupt onset of obsessive–compulsive symptoms and/or restrictive eating behavior, accompanied by at least two of the following additional symptoms: anxiety, sensory hypersensitivity, depressive mood, motor symptoms (such as dysgraphia, tics, or movement stereotypies), behavioral regression, sudden deterioration in academic performance (including memory and concentration difficulties, ADHD), mood lability (irritability, aggressive or markedly oppositional behavior), and somatic signs (including sleep disturbances, mydriasis, enuresis, and other urinary symptoms). The impairment is significant compared to the patient’s baseline functioning and cannot be better explained by a known neurological or other medical disorder. (This also includes patients in whom the abrupt onset occurred in the more distant past, provided they remain symptomatic.)
Exclusion criteria
Exclusion criteria: Evidence of other neurological or medical disorders that better explain the symptoms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the number of patients who meet the inclusion criteria and are recorded in participating hospitals during the study period. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is the assessment (standardized questionaire) of current diagnostic and therapeutic approaches, as well as the healthcare situation in Germany for patients presenting with PANS symptoms. | — |
Countries
Germany
Contacts
Public ContactPia Turowski
Institut für Rettungs- und Notfallmedizin, UKSH, Campus Kiel
Outcome results
None listed